Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
Go back to Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism| (NASDAQ: RZLT) | Delayed: 3.91 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.91 | 52 Week High | $ | |||
| Open | $3.91 | 52 Week Low | $ | |||
| Day High | $3.91 | P/E | N/A | |||
| Day Low | $3.91 | EPS | $ | |||
| Volume | 366 | |||||
